- Home
- IFRX vs DTIL Comparison
IFRX vs DTIL Comparison
Compare IFRX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- DTIL
- Stock Information
- Founded
- IFRX 2007
- DTIL 2006
- Country
- IFRX Germany
- DTIL United States
- Employees
- IFRX N/A
- DTIL N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- DTIL Health Care
- Exchange
- IFRX Nasdaq
- DTIL Nasdaq
- Market Cap
- IFRX 53.5M
- DTIL 55.3M
- IPO Year
- IFRX 2017
- DTIL 2019
- Fundamental
- Price
- IFRX $1.27
- DTIL $7.15
- Analyst Decision
- IFRX Strong Buy
- DTIL Strong Buy
- Analyst Count
- IFRX 5
- DTIL 2
- Target Price
- IFRX $7.40
- DTIL $47.00
- AVG Volume (30 Days)
- IFRX 486.5K
- DTIL 140.5K
- Earning Date
- IFRX 11-07-2025
- DTIL 11-03-2025
- Dividend Yield
- IFRX N/A
- DTIL N/A
- EPS Growth
- IFRX N/A
- DTIL N/A
- EPS
- IFRX N/A
- DTIL N/A
- Revenue
- IFRX $191,224.00
- DTIL $1,261,000.00
- Revenue This Year
- IFRX N/A
- DTIL N/A
- Revenue Next Year
- IFRX $1,216.24
- DTIL $135.19
- P/E Ratio
- IFRX N/A
- DTIL N/A
- Revenue Growth
- IFRX 54.36
- DTIL N/A
- 52 Week Low
- IFRX $0.71
- DTIL $3.61
- 52 Week High
- IFRX $2.82
- DTIL $9.20
- Technical
- Relative Strength Index (RSI)
- IFRX 47.77
- DTIL 80.86
- Support Level
- IFRX $1.14
- DTIL $5.29
- Resistance Level
- IFRX $1.44
- DTIL $5.94
- Average True Range (ATR)
- IFRX 0.14
- DTIL 0.36
- MACD
- IFRX -0.03
- DTIL 0.16
- Stochastic Oscillator
- IFRX 26.00
- DTIL 95.69
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.